Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 12/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688442 | 0.93 | PTGER3 (0.42) | PTGER3CNR2SLC22A12MAPTCTSA | |
| SCHEMBL688053 | 0.92 | PTGER3 (0.43) | PTGER3CNR2SLC22A12MAPTCTSA | |
| SCHEMBL687712 | 0.91 | PTGER3 (0.43) | PTGER3CNR2SLC22A12MAPTCTSA | |
| SCHEMBL687796 | 0.90 | CTSA (0.46) | PTGER3CNR2SLC22A12MAPTCTSA | |
| SCHEMBL686799 | 0.90 | PTGER3 (0.51) | PTGER3CNR2SLC22A12MAPTCTSA | |
| SCHEMBL688170 | 0.89 | PTGER3 (0.41) | PTGER3CNR2SLC22A12MAPTITGB1 | |
| SCHEMBL688284 | 0.89 | PTGER3 (0.43) | PTGER3CNR2SLC22A12MAPTCTSA | |
| SCHEMBL686986 | 0.89 | MEN1 (0.42) | PTGER3CNR2SLC22A12MAPTCTSA | |
| SCHEMBL688379 | 0.89 | PTGER3 (0.42) | PTGER3CNR2SLC22A12CTSACYP26A1 | |
| SCHEMBL687873 | 0.88 | PTGER3 (0.42) | PTGER3CNR2SLC22A12MAPTITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | PTGER3 2942/4885CNR2 2011/4885SLC22A12 2041/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | PTGER3 2649/4885CNR2 1897/4885SLC22A12 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.